drugset / Trial / NCT01684241
RBL001/RBL002 Phase I Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
Clinical first-in-human dose escalation study evaluating the safety and tolerability of intranodal administration of an RNA-based cancer vaccine targeting two tumor-associated antigens in patients with advanced melanoma
Timeline
- Start
- 2012-06
- Primary completion
- 2015-05
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RBL001 | Vaccine | 50 ug | Other |
| Subject | RBL001 | Vaccine | 100 ug | Other |
| Subject | RBL001 | Vaccine | 300 ug | Other |
| Subject | RBL001 | Vaccine | 600 ug | Other |
| Subject | RBL002 | Vaccine | 50 ug | Other |
| Subject | RBL002 | Vaccine | 100 ug | Other |
| Subject | RBL002 | Vaccine | 300 ug | Other |
| Subject | RBL002 | Vaccine | 600 ug | Other |